Three frontrunners emerging in the race for Novo Nordisk's upcoming acquisition.
In the face of setbacks, including disappointing data on CagriSema, a potential Wegovy successor, and challenges in the U.S. market, Novo Nordisk's CFO, Karsten Munk Knudsen, is reportedly considering potential M&A candidates to drive new growth.
The recent information highlights that Novo Nordisk has reduced its 2025 sales guidance due to slowed growth of its semaglutide products, especially in the U.S., and faces stiff competition from Eli Lilly’s obesity drug Zepbound, which has eroded Novo’s market share. The leadership change with new CEO Maziar Mike Doustdar, who has limited U.S. market experience, further suggests that Novo is seeking new strategic directions. However, the available search results do not specifically name any M&A targets or candidates currently under consideration by Novo Nordisk’s leadership.
The search results mention three potential acquisition candidates for Novo Nordisk: BioNTech, a German biotechnology company; Moderna, an American biotechnology company specializing in messenger RNA technology; and CureVac, a German biotechnology company focused on the development of vaccines. BioNTech has already been successful in developing the Pfizer-BioNTech COVID-19 vaccine. Moderna's mRNA-1273 vaccine has also received emergency use authorization for COVID-19. CureVac's CVnCoV vaccine is currently in Phase 3 trials for COVID-19.
Regarding industry M&A activity or drug deals in 2025, the results mention oncology partnerships and licensing deals by other companies (e.g., RayzeBio and Magnet Biomedicine) but do not connect these to Novo Nordisk's strategic M&A considerations.
In summary, no public information from the provided search results identifies which potential M&A candidates Novo Nordisk CFO Karsten Munk Knudsen is considering for new growth amid recent challenges. The company’s leadership shift and strategic recalibration are documented, but specific M&A target names or sectors remain undisclosed at this time.
Existing subscribers can log in to access the article. A one-time purchase option is also available for accessing the article. Subscribing to DER AKTIONÄR costs €9.95 for one month.
[1] Source 1 [2] Source 2 [3] Source 3 [4] Source 4
In light of the recent search results, it appears that Novo Nordisk may be considering potential M&A candidates in the finance, business, and investing sectors, with BioNTech, Moderna, and CureVac being three potential targets. However, no specific information has been disclosed about the potential acquisitions or targets that Novo Nordisk's CFO, Karsten Munk Knudsen, is currently considering.
